- Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 StudyYukitomo Urata
Department of Rheumatology, Seihoku Chuo Hospital, Gosyogawara, Japan
Ann Rheum Dis 71:534-40. 2012..6 and matrix metalloproteinase (MMP) 3 normalisation offers better outcomes than either target alone in early rheumatoid arthritis (RA) at 56 weeks: Treating to Twin Targets (T-4) Study...
- Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patientsYukitomo Urata
Department of Rheumatology, Seihoku Chuo Hospital, 41 Nunoyacho, Gosyogawara, 037 0053, Japan
Mod Rheumatol 21:16-23. 2011..9 (p = 0.008) and 6.9 (p = 0.001), respectively. RA patients with resolved hepatitis B need careful monitoring when receiving biologic agents, regardless of HBV DNA levels...